Literature DB >> 25641130

Serotonin is involved in the psychostimulant and hypothermic effect of 4-methylamphetamine in rats.

Mar Rubio1, Raúl López-Arnau1, David Pubill1, Elena Escubedo2, Jorge Camarasa1.   

Abstract

4-Methylamphetamine (4-MA) has recently emerged as a designer drug of abuse in Europe and it is consumed always with amphetamine. There have been reported some deaths and non-fatal intoxications related to 4-MA. We investigated the changes in locomotor activity and body temperature after 4-MA administration to male Sprague-Dawley rats. Our experiments were carried out at a normal or high ambient temperature. 4-MA (2.5-10mg/Kg, given subcutaneously) increased, in a dose-dependent manner, the horizontal locomotor activity that was significantly reduced by ketanserin, p-cholorophenylalanine (pCPA) or haloperidol, but not by pindolol. In addition, we have studied the effect of 4-MA on core body temperature by means of an implanted electronic thermograph, enabling continuous measurement of body temperature. We observed a dose-dependent hypothermic response to 4-MA that reached a maximum 45 min after a single injection. We also evidenced slight tachyphylaxis to the hypothermic effect when 4-MA was administered four times in a 2h interval. The pre-treatment of animals with pCPA or pindolol, but not with ketanserin, fully abolished the hypothermic effect of 4-MA. With all that, we conclude that hypothermia induced by 4-MA is due to the release of 5-HT which activates postsynaptic 5-HT1A receptors.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  4-Methylamphetamine; Hypothermia; Locomotor activity; Rat; Serotonin

Mesh:

Substances:

Year:  2015        PMID: 25641130     DOI: 10.1016/j.neulet.2015.01.075

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

1.  N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability.

Authors:  Ernesto Solis; John S Partilla; Farhana Sakloth; Iwona Ruchala; Kathryn L Schwienteck; Louis J De Felice; Jose M Eltit; Richard A Glennon; S Stevens Negus; Michael H Baumann
Journal:  Neuropsychopharmacology       Date:  2017-05-22       Impact factor: 7.853

Review 2.  How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe.

Authors:  Raquel Santos-Toscano; Amira Guirguis; Colin Davidson
Journal:  Br J Clin Pharmacol       Date:  2020-02-23       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.